Try our Advanced Search for more refined results
Life Sciences - June, 2023
355 articles
- Opioid Judge Mulls Liability Of 'Don Draper' McKinsey
- Biz Group Presses Tai On Lingering Mexico Trade Frictions
- Talc Claimants Call J&J Unit's 2nd Ch. 11 A Tort Dodge
- EU, Pfizer Strike Pandemic Prep Deal Via €5B Health Program
- Feds Deny Liability For ICE Detainee's COVID-19 Death
- Amgen, Horizon Lodge Constitutional Attack On FTC
- Gilead, Teva Defeat $3.6B HIV Drug Antitrust Case At Trial
- DC Circ.'s Perchlorate Ruling Means Regulatory Restart
- Once-Dreary IPO Outlook Brightens For Second Half Of 2023
- Appellate Funding Disclosure: No Mandate Is Right Choice
- The Fed. Circ. In June: A Lesson On Citing With Particularity
- UK Litigation Roundup: Here's What You Missed In London
- Wachtell Guides Bausch & Lomb In $2.5B Novartis Deal
- Justices Order FCA Do-Overs After SuperValu Intent Ruling
- What IP Attys Need To Know About Del. Judge Nominee Hall
- Calif.'s Insulin Cost Suit Against CVS Sent Back To State Court
- Pharma CEO, Others Get Prison Time In $80M Medicare Fraud
- Bans On Trans Youths' Health Care Get Blocked In Tenn., Ky.
- Tennessee Accuses 3M, DuPont Of PFAS Foam Contamination
- Ex-Alexion VP, Police Chief Charged In Insider-Trading Sweep
- DOJ Fights AmerisourceBergen's Dismissal Bid In Opioid Suit
- Case Law Is Mixed On D&O Coverage For Gov't Investigations
- Atty For Theranos Exec Joins Seattle's Corr Cronin
- COVID Drug Maker Tevogen To Go Public Via SPAC At $1.2B
- Eli Lilly To Buy Mass. Biopharmaceutical Biz For Up To $300M
- Key PTAB Priorities And Changes Under Vidal
- Pfizer Insider Charged With Profiting Off COVID Drug Info
- J&J Took Initiative On 2019 Talc Recall, Jury Hears
- Attys For Gilead, Drug Buyers Trade Barbs As $3.6B Trial Ends
- Accused Atty Says Feds' Theory Faulty In Biz Takeover Case
- Judge Says Full Freeze Of NC Abortion Law Is 'Off The Table'
- Judge Says Pharma Industry Has 'Perverted' Hatch-Waxman
- DOJ Targets Telehealth, Opioids In $2.5B Fraud Sweep
- Eligibility Bill Gives Attys Relief, Even With 'Squishy' Terms
- Sanofi Clears Cancer Drug From More Generic Competition
- UK Health Co. Wants Out Of US Psilocybin Therapy Theft Suit
- FTC Order May Guide Cos. In Avoiding Pyramid Scheme Label
- Preparing For FDA's Surprise Foreign Drug Inspection Regime
- Drug Pricing Law Could Have Unintended Consequences
- DePuy Wins Pa. Spinal IP Infringement Case Mid-Trial
- Pierre Fabre Can't Clean Out All Of Benzene Shampoo Suit
- What's Next For Colorado's Psychedelics Legalization?
- HIV Drug Buyers Urge $3.6B Verdict Against Gilead And Teva
- Abortion Providers And SC Fight Before State's Top Court
- AliveCor Asks Fed. Circ. To Flip Partial Loss In Apple ITC Row
- Medtronic Rival Defends Surgical Device Antitrust Case
- J&J Talc Unit Dismissal Trial Focuses On Funding Agreements
- Mass. Pharmacy To Pay $10M For Missing Opioid 'Red Flags'
- 2 Reps. Float House Companion To Senate PTAB Overhaul Bill
- Paratek Investor To Withhold Board Votes, Citing Concerns
- PTAB Rightly Axed Medytox Wrinkle Patent, Fed. Circ. Says
- SuperValu's Lesson: Always Be Building An FCA Defense
- Texas Firms' Paxil Fee Fight Survives Anti-SLAPP Challenge
- McCarter & English Adds Former J&J Deputy General Counsel
- Dentons Adds IP Pro From Steptoe & Johnson
- NBA Players Must Avoid Legal Fouls In CBD Deals
- Upside For Advertisers After 2nd Circ. False Ad Suit Revival
- Cellino Can't Get Fees From Ga. Mesh Lawsuit, Atty Claims
- NC Dental Board Wants To Ax Kroger's Ohio Opioid Subpoena
- Supreme Court's Opioid Edict Spawns 'Troubling' Divisions
- 3 Ways New Senate Bill Would Reshape PTAB Litigation
- Gilead Didn't Pay Teva In HIV Drug IP Deal, Economist Says
- Attys Want $76M After $255M Juul Settlement
- Judge Lets NC Republican Leaders Jump Into Abortion Suit
- Detroit Tigers, Fired Employee Must Mediate Civil Rights Suit
- Dechert, Shearman Rep On MedTech's $370M SPAC Merger
- Optum To Buy Amedisys For $3.3B, Derailing Option Care Deal
- A Comprehensive Overview Of PTAB Trends For Biologics
- Astellas, Aon Ink $9.5M Deal In Suit Over 401(k) Management
- 3M Strikes Confidential PFAS Deal With Fla. City
- Insys Founder Kapoor Released After 2 Years In Prison
- Shkreli-Linked Pharma Co. Strikes Deal Over Share Sale
- No Jurisdiction In 2 Cook Medical MDL Suits, Panel Rules
- Fed. Circ. Decision Offers Lessons In Analogous Art Tests
- Mallinckrodt To Make Payments On $1.7B In Term Loans
- Walmart Investors Balk At Stay Request In Del. Opioid Suit
- How Attys Can Avoid Exposing Their Firms To Cyberattacks
- Catching Up With Delaware's Chancery Court
- A Need To Be Big: US Law Firms Kept Foot On Gas In 2022
- The Law360 400: Tracking The Largest US Law Firms
- 10 Years Of The 10 Biggest US Firms
- Ark. Pot Biz Urges 8th Circ. To Revive Discrimination Suit
- Attys Tell Biden Admin Pot's Schedule 1 Status 'Indefensible'
- McKinsey Nears Opioid MDL Deal With Tribes, Insurance Plans
- Ex-FTC Official Pans Claim Gilead-Teva Deal Hurt Competition
- CVS Settles Calif. Ex-Pharmacy Tech's Disability Bias Suit
- Biden Orders DOL To Expand Birth Control Access
- NC Republican Leaders Want To Jump Into Abortion Ban Suit
- Health Hires: MapLight, Wilson Sonsini, Mayer Brown
- 3 Questions Lingering For Benefits Attys 1 Year After Dobbs
- 6 States Join FTC's Challenge To Amgen's $28B Horizon Buy
- NM High Court Clarifies State's Rules On Duplicative Damages
- AG's Eli Lilly Insulin Probe Needs Mich. High Court Action
- Rare FDA Move Shows Stance On Remote Monitoring Devices
- Ex-Trulieve Pot Biz Worker Says He Was Fired For FMLA Leave
- ExecuPharm Must Face Claims In 'CL0P' Hacking Case
- Chinese Chemical Cos. Charged In Major Fentanyl Bust
- PharmacyChecker Defends Blacklist Suit Against LegitScript
- Pa. Pharmacy Knew Doc Overprescribed Meds, Woman Says
- Icon Ken Feinberg Shares Lessons From A Life Mediating
- Princeton Wins Bid To Depose Professor In Manuscript Battle
- NJ Law Firm Hit With Malpractice Claims Over Atty Fees
- What Purdue Ch. 11 Means For Future Of Third-Party Releases
- Trial Set In Ga. Woman's Pelvic Mesh Case
- Virginia 'Rocket Docket' Slowdown Is Likely A Blip
- FDA Publishes Draft Guidance On Psychedelic Drug Research
- UK Litigation Roundup: Here's What You Missed In London
- Taxation With Representation: Latham, Kirkland, Fenwick
- Tillis, Coons Bills Aim To Limit Invalidation Rulings
- Jazz Pharma Says FDA Again Defied Orphan Drug Exclusivity
- How Dobbs Has Changed The Data Privacy Landscape
- ArcherDX Says Natera Dragged Feet On Patent Filings
- NC AG Agrees With Those Suing Him: Abortion Ban Unlawful
- J&J Talc Unit's Ch. 11 Suit Injunction Extended To August
- How A Top Anti-Abortion Atty Sees Dobbs 1 Year Later
- How A Top Abortion-Rights Atty Sees Dobbs 1 Year Later
- Abortion Litigation To Watch As Dobbs Decision Turns 1
- State Lawmakers Reveal How They Move Psychedelics Policy
- Lozenge Buyers Push Back On P&G Bid To Toss False Ad Suit
- 3M Strikes $12.5B Deal Over PFAS Contamination
- Lyme Disease Test 'Useless,' 'Inaccurate,' Suit Says
- Preparing For Md. Adult-Use Cannabis: Operations And More
- Applying Hatch-Waxman To Cell And Gene Therapies
- Ex-Jurist's $1,550-Hour Gilead Witness Job Not Ethics Issue
- Feds Fight Gilead's Win In Billion-Dollar HIV Patent Trial
- Drug Lobby Widens Industry Pricing Challenges To Texas
- Va. Judge Revives 2 Patents Axed In $17M Bone Screw Trial
- IAnthus Stole $4.5M From Cannabis Co., Suit Claims
- Sandoz Fights $39M Loss In Suit Over Eyelash Growth Serum
- 7th Circ. Reverses Ceramic Co.'s Win In Asbestos Suit
- 11th Circ. Backs Vacating Arb. Award In Medical Device Fight
- Millennium Lab Trust Needs More Time For $1B JPMorgan Suit
- Where State Abortion Ballot Measures Stand After Dobbs
- 5th Circ. Backs Collective Cert. In Therapists' OT Suit
- FTC Urges 2nd Circ. To Revive Bystolic Antitrust Case
- Zoetis Seeks Access To Stable In Antibiotic Horse Death Suit
- Vanda Asks Full Fed. Circ. To Review Axed Sleep Med Patents
- Attys Say 'Fractured' Pot Reform A Lesson For Psychedelics
- PTAB OKs Most Of Amended Patent On Transport Containers
- Texas District Attys Want Abortion Ban Challenge Dismissed
- Preparing For Md. Adult-Use Cannabis: Licensing Provisions
- FTC's Amgen-Horizon Protest Raises Conglomerate Concerns
- Gilead-Teva Deal Costs To Buyers Top $3.6B As Plaintiffs Rest
- 7th Circ. Backs TRT-Maker Actavis In Man's Heart Attack Suit
- 2 Firms Will Steer FibroGen Stockholder Suit In Chancery
- Supreme Court Remands Medicaid Rows To 4th, 7th Circs.
- Sanofi Needn't Indemnify German Pharma Co. In Zantac Suits
- Senate Confirms Abortion Rights Atty To 1st Circ.
- High Court Underscores DOJ's Role In Policing FCA Litigation
- Republicans Keep Up Complaints About WTO COVID Waivers
- 'No Settlement' Coming In Pharma Tech Exec's Contract Suit
- 5 Management Tips To Keep Law Firm Merger Talks Moving
- What 3rd Circ. Niaspan Decision Means For Class Cert.
- AI-Focused Spinal Imaging Co. Hits Ch. 11 After Layoffs
- 2 Firms Build $2.4B Sale Of SF Biopharmaceutical Biz
- Conn. Atty Wants New Judge After Polling Gaffe In SEC Case
- Law360 Names 2023's Top Attorneys Under 40
- Calif. Jury Finds Urologist Stole Penile Implant Trade Secrets
- Bristol-Myers Joins Big Pharma Attack On Price Negotiating
- Harvard Profs Battle Over $1.5B Antitrust Damages Estimate
- High Court's FCA Ruling Reopens Constitutionality Question
- Arthrex Loses Bid For Director Review Of 2017 PTAB Ruling
- Wash. Judge Tosses Chilean Co.'s Row With Supplier
- Outcome Ex-CEO Fights Forfeiture After $1B Fraud Conviction
- Walgreens Must Face Bulk Of Kids' Cough Medicine Suit
- Pharma Co. Sues To Stop Sale Of Shkreli's Shares In Ch. 11
- Iowa Supreme Court Blocks Fetal Heartbeat Abortion Ban
- Providers Sue To Undo 'Nonsensical' NC Abortion Limits
- Vidal To Scrutinize Ax Of 5 Patents Over Withheld Data
- Cava's Scorching Debut Could Help Thaw A Frozen IPO Market
- Kaiser Permanente Gets Tax Credit Claims Cut Permanently
- AngioDynamics Wants Atty Fees From Bard In Patent Case
- Ga. Doc Liable For Metal Poisoning False-Billing Scheme
- SmileDirect Drops Antitrust Suit Against Calif. Dental Board
- Purdue Seeks Ch. 11 Stay Extension To Implement Its Plan
- Texas High Court To Take On Fen-Phen Atty Malpractice Fight
- Recent Bills Show Congress' Growing Maturity On Cannabis
- Immunomedics Attys Win $12M Fee In $40M Data Scandal Deal
- Law360's 2023 Life Sciences Editorial Advisory Board
- UK Litigation Roundup: Here's What You Missed In London
- High Court Backs Broad FCA Dismissal Authority For Gov't
- Amgen, Samsung Test Blood Drug Patent In 'Biosimilars' Race
- Penile Implant 'Trade Secrets' Are Urology 101, Jury Told
- PwC Must Face Valeant Investor Suit Over Missed 'Red Flags'
- Hospital Hit With $8M Verdict Over Botched Cesarean Section
- Prominent Kirkland Litigator Steps Away From Practicing Law
- Hospitals Seek Class Counsel In Opioid MDL
- Inovio Investors Get Derivative Deal OK'd Over Vaccine Claims
- IP Forecast: It's Deja Vu In $2.75B Cisco Patent Row
- AbbVie Unit Launches Patent Suit Over Cancer Drug
- Colgate-Palmolive Wants Justices To Undo $300M ERISA Loss
- Group's Delay Enforcing $500K Deal Draws Judge's Scrutiny
- Bestway Offers Store Sales Over CMA Deal Concerns
- What The Data Says About FDA Responses To FOIA Requests
- Cybersecurity Is Biggest Compliance Threat, Survey Says
- LabMD's Malpractice, Fraud Claims In Ga. Sent To Arbitration
- Fed. Circ. Args Don't Bode Well For Patent Term Adjustment
- The Texas Two-Step May Be Losing Steam
- NY AG Inks $6.9M Deal Over Roundup Safety Ad Claims
- Battery Tech Firm Cancels SPAC Merger As More Deals Fail
- Mallinckrodt Skips Bond Interest Bill While Mulling Options
- Perkins Coie Adds DC Partner, Building Food Industry Focus
- FTC Pharma Merger Digest May Offer Policy Clues
- The Road Ahead For Rite Aid And Other Troubled Retailers
- EEOC Drops Age Bias Suit Over Novo Nordisk Transfer Denial
- Reed Smith Continues Partner Hires With Investment Pro
- Ex-FDA Official Tells Antitrust Jury Generic Rivals Were Ready
- PBM Trade Group Balks At Move To Curtail Compensation
- Drop In Ransomware Attacks Boosts Cyber Insurers In 2022
- Ex-ADI Engineer Asks To Delay Prison During 1st Circ. Appeal
- Fed. Circ. OKs Denial Of Blood Pressure Treatment Patent App
- 3 Abortion Enforcement Takeaways 1 Year After Dobbs
- Rethinking In-Office Attendance For Associate Retention
- 4 Paths To Defending Calif. Unfair Competition Claims
- Lawmakers Push FDA To Finish E-Cig Applications
- UC Fights Teva's Bid To Invalidate Prostate Cancer Patent
- Fintiv Discretionary Denials Seem To Be Back At PTAB
- Gilead-Teva Patent Deal Cost Drug Buyers Over $2B, Jury Told
- Spinal Device Co. Gets $6M Bond Cut In Trade Secrets Suit
- Monsanto's 11th Circ. Appeal Deal Queried In Roundup Case
- Ch. 11 Dismissal Trial A Gating Issue In J&J Talc Unit Case
- Holmes Opposes Feds' Post-Prison Victim Payment Plan
- Biotech Co. Says SEC Can't Back Up Asset Freeze
- DOJ's 'Hyperbolic' Opioid Suit 'Falls Far Short,' Rite Aid Says
- GOP Lawmakers, AGs Back Illumina Against FTC At 5th Circ.
- What Innovators Can Expect In The Patent World After Amgen
- Cooley, Latham Steer Turnstone Biologics' $86M IPO Filing
- Crowell & Moring Exiting Walgreens Suit Over Conflict Claims
- DOJ Sees Far-Reaching Victory In High Court's FCA Ruling
- Software Fair Use Protections Attacked At DC Circ.
- Hospitals Call Ex-Doctor's Challenge To Vax Deal 'Mudslinging'
- Amgen, Horizon Blast FTC's 'Speculation On Speculation'
- Bladder Drug Patent Fails To Survive In Del.
- Despite Its Plan Objections, UST Also Won In Purdue Ch. 11
- Icahn's Persistence On Illumina Pays Off With Series Of Wins
- Catching Up With Delaware's Chancery Court
- USPTO's Speed On Some China Patents Bears A Closer Look
- Mont. AG Latest To Question National Org. Over Funds Use
- Ex-GC Accuses Health Tech Co. Of Toxic Environment
- As Tech Market Heats Up, More Firms Are Ready For Denver
- Murdaugh Trials Offer Law Firms Fraud Prevention Reminders
- DLA Piper Litigator Jumps To Arnold & Porter In Houston
- Gilead-Teva IP Deal Struck Despite Invalidity Issues, Jury Told
- 'I Get Upset,' Penile Implant Doc Apologizes To Judge, Jury
- Big Biz Brings New Challenge To HHS Drug Price Negotiations
- LabMD Hit With Sanctions Bid Over Ga. Lawsuit
- FibroGen Investors Seek Sanctions For Destroyed Evidence
- Rival Presses Treble Damages Bid Against Philips Medical
- 1st Circ. Upholds Vitamin Shoppe's Win In Muscle Powder Suit
- 9th Circ. Nixes P&G False Ad Suit, Calls Label 'Concerning'
- Del. Justices Uphold Atty Fee Denial In Mooted Novavax Suit
- Pfizer Mismanaged Fees For $22B 401K Plan, Employees Say
- Boston Scientific Wins $158M In Cook Medical Patent Trial
- What Courts Say About Workers' Comp And Medical Marijuana
- Pharmacy Compliance Exec Guilty Of $50M Medicare Fraud
- AstraZeneca, Quell Make Collaboration Deal Worth Up To $2B
- UK Litigation Roundup: Here's What You Missed In London
- New Mexico Inks $500M Opioid Deal With Walgreens
- Lowenstein Sandler Criticized In Conn. Biz Document Dispute
- Group Backs Illumina Attack On FTC Structure At 5th Circ.
- Chilean Co. Asks Court To Stop Supplier's Sales To Rival
- Cherokee Nation Sues Opioid Distributor After DEA Discipline
- IP Forecast: Google To Face $33M Audio Patent Trial
- FTC Mulling Juul-Altria Settlement Offer Staffers Oppose
- Japanese Pharma Giant Eisai Hit By Ransomware Attack
- Lannett Gets OK For $511M Debt-Swap Ch. 11 Plan
- NY AG Sues Anti-Abortion Group For Interfering With Clinics
- MiMedx Execs To Pay SEC Nearly $2M To End Fraud Claims
- Tribe, Green Groups Say Fruit Company Is Polluting Wetlands
- AI-Fueled Innovation Poses Patentability Challenges
- Nevada, Teva Ink $193M Deal Over Opioid Crisis
- CVS Must Face Insulin Price Suit In State Court, Calif. Says
- Teva Atty Says Gilead Deal Followed Bad News On FDA Filing
- Senators Try To Come To Grips With AI Inventorship
- Ex-Insys CEO Says Legal Fee Clawback Unsupported In Ch. 11
- PharmacyChecker Denied Appeal After Blacklist Suit Tossed
- Judge Reverses Course On Jurisdiction In False Ad Suit
- Pot Cos., Advocates Partner To Push Cannabis Rescheduling
- Amazon Teams Up With Canon, Yeti On Joint Counterfeit Suits
- Firm Tips For Helping New Lawyers Succeed Post-Pandemic
- Crowell & Moring Blasted Over Fees Clause In Walgreens Suit
- SPAC Extends Merger Timeline After Investors Redeem $11M
- What To Know About Recent Trends In PTAB Sanctions
- Ultrasound Tech Co. Must Face Fujifilm's Patent Claims
- Biopharma Co. Hit With Firing Bias Suit Over COVID Vax Rules
- Pfizer, Moderna Sued Over MRNA Tech In COVID Vaccines
- Merck Brings Jones Day Brawler & Punchy Tone To HHS Fight
- Providers Challenge Kansas Abortion Restrictions
- Ex-Gilead GC Says He Didn't Calculate Teva's Gain In IP Deal
- Judge Hesitant To Advise Michigan Justices On Insulin Probe
- Alkermes Raises Revenue Forecast After Arbitration Award
- Wash. Panel Disputes J&J Analysis On Protecting Health Data
- TRIPS Vaccine Waiver Was A Bad Call, GOP Reps. Say
- Case Against Takeda, Eli Lilly Gets Partial Class Cert.
- Talc Claimants Object To Fee Deal For J&J Plan Supporters
- Illumina Tells 5th Circ. Grail Case 'Flagrant' Overreach
- Fate Execs Sued After $50M Deal With J&J Unit Falls Apart
- Prepping Your Business Ahead Of Affirmative Action Ruling
- AI-Focused Biotech Seeks Chapter 11 To Rework $9M Debt
- 4 Emerging Risks For US Insurance Markets
- Judge Blocks Fla. Ban On Trans Health Care
- 3 Firms Build $462M Sale Of Paratek Pharmaceuticals
- Ex-Gilead VP Says Execs Gamed Out Truvada Generic Date
- Circuits 'Didn't Get The Memo' On Opioid Cases, Justices Told
- Mallinckrodt Considers New Bankruptcy Over Opioid Payment
- Chancery Won't DQ Selendy Gay In Fortis-J&J Earnout Suit
- 3rd Circ. Rejects Rehearing Bid From Niaspan Buyers
- Shareholders, Regulators Urge Rejection Of Clovis Ch. 11 Plan
- JPML Consolidates Thyroid Drug Hearing-Loss Suits In Illinois
- Ex-Ascension Doc Says Mich. Settlement Thwarts Indiana Suit
- Psychedelics Bill Roundup: Nevada OKs New Working Group
- Amedisys Mulls $3.2B Optum Bid Despite Option Care Deal
- Tackling Judge-Shopping Concerns While Honoring Localism
- Medtronic Loses Catheter Patent Fight At Fed. Circ.
- J&J Wants Review Of Talc Attys' Media Contact Subpoenas
- 3 Firms Lead CERo Therapeutics $145M SPAC Merger
- 3 IP Attys Join Cooley From Fish & Richardson
- 8th Circ. Won't Revive Heart Valve Contract Dispute
- Judge Calls Apple's Conduct In Smartwatch Row 'Careless'
- Premera Joins Takeda Antitrust Litigation Over IBS Drug
- BioMarin Hit With Del. Derivative Suit Over Missed Deadline
- Care One Fired Sales Rep For Compliance Concerns, Suit Says
- Mich. Appellate Judges Split On COVID Tolling Orders
- NJ Lab CEO Accused Of Wrecking Rival Lab's Hardware
- Lannett Reaches Deal With Creditor Committee In Ch. 11
- No Easy Out For FCA Defendants After Justices' Ruling
- How Telemedicine Providers Can Adapt To Post-COVID Rules
- Fed. Circ. Urged To Undo $2.3M Bone Imaging IP Verdict
- Surge In Secondary Offerings Raises Hopes For IPO Rebound
- Is SEC's Universal Proxy Rule Living Up To The Hype?
- How Attorneys Can Help Combat Anti-Asian Hate
- US Moves Toward Legal Dispute Over Mexico's Corn Policy
- AGs Cut $102M Deal With Indivior In Suboxone Antitrust Case
- Morgan Lewis Adds Life Sciences Atty From Goodwin Procter
- UK Litigation Roundup: Here's What You Missed In London
- Congress Needs To Enact A Federal Anti-SLAPP Statute
- Thomas Burnishes False Claims Act Crown With 9-0 Decree
- Sorrento Ends LA Times Owner's Drug Claims, For Now
- J&J Tells Jury 1970s Talc Findings Irrelevant Now
- High Court Opens Up Uncertainty On FCA Recklessness
- FTC Wants 5th Circ. To Slow Down Illumina's Grail Appeal
- Congress Proposes Permanently Lifting Baby Formula Duties
- Judge Wipes Out Bard's Jury Win In Medical Device IP Feud
- Ax Of 5 Patents Shows PTAB's Hard Line On Duty Of Candor
- Gov't Told To Keep Fighting 'Unexpected' HIV Patent Loss
- 62 Lawmakers Call To Escalate Corn Dispute With Mexico
- Georgia Drops Federal Contractor Vaccine Case Against Biden
- DC Judge Rips Crowell Attys Over Walgreens-Humana Fight
- Philips Scoffs At Rival's Bid For Treble Damages After IP Trial
- Former FDA Official Joins Morgan Lewis In DC
- Global Issues In EU's Licensing Plans For Essential Patents
- Bristol-Myers, Fired Workers End COVID Vax Bias Suit
- Justices Say FCA Liability Hinges On Defendants' Beliefs
- Biotech Biz Buys COVID Test Kit Maker For £10.4M
- LivaNova Hits Back In €21M Suit Over Heart Biz Acquisition